Introduction {#sec1-1}
============

Thrombosis is one of the leading causes of death worldwide.\[[@ref1]\] In India, the incidence of venous thromboembolism is reported to be 17.5 per 10,000 hospital admissions. Risk factors (surgery, malignancy, obesity, increased age) for venous thromboembolism has been reported in 54% of hospitalized patients.\[[@ref2]\] Risk of venous thromboembolism in an individual is influenced by the combination of his or her baseline predisposition for thrombosis (deficiency of natural clotting inhibitors or elevated procoagulants or increased fibrinolytic factors) and the magnitude of the acquired risk factors (pregnancy, smoking, injury, increasing age, obesity, surgery, immobility).\[[@ref3]\] Amongst these, activated protein C resistance is the most common trigger and is seen in 20-50% patients with inherited thrombophilia. Factor V Leiden (FVL) mutation (1691G \>A; R506Q) accounts for 92% of cases with activated protein C resistance,\[[@ref4]\] making it the most common genetic risk factor for thromboembolism worldwide.\[[@ref5][@ref6]\] Heterozygous and homozygous carriers of the mutation have a seven-fold and 80-fold increase in thrombosis risk, respectively.\[[@ref3]\] This maybe further augmented by pregnancy (9-fold), use of oral contraceptives (36-fold), and hormone replacement therapy (13- to 16-fold).\[[@ref4]\] Carriers of FVL are also known to have an earlier age of onset of thrombosis as compared to non-carriers.\[[@ref7]\]

Studies have indicated the use of prophylactic anti-coagulation therapy in carriers of FVL during high-risk situations known to provoke thrombosis such as hospitalization for surgery or other medical reasons.\[[@ref8][@ref9]\] Latest Guidelines by the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel\[[@ref10]\] suggest six months of post-partum prophylactic anti-coagulation therapy (Vitamin K antagonists with target INR 2-3) for pregnant women known to be homozygous for FVL or Prothrombin 20210A mutation irrespective of their history of venous thromboembolism.

Warfarin and Acenocoumarol are the most widely prescribed anti-coagulant for the treatment and prevention of venous and arterial thromboembolic events. Although very effective, usage of these drugs is limited by the difficulty in optimizing therapeutic dosage and fear of inducing bleeding or severe hemorrhage. Prospective studies carried out in tertiary health care centers in India\[[@ref11][@ref12]\] and the world\[[@ref13]\] revealed that 5% to 6.9% of all hospital admissions were due to adverse drug reactions, of which warfarin-induced bleeding was ranked as one of the most common causes. Both genetic and clinical factors are known to contribute towards inter-individual variation to warfarin. In year 2010, the Food and Drug Administration, U.S.A., approved revised prescribing information on warfarin (Coumadin), stressing on the effect of the three polymorphisms (*CYP2C9* ^\*^2, ^\*^3 and *VKORC1*-1639G \>A) on dose and bleeding with specific recommendations of dose ranges for individuals with various genotype combinations.\[[@ref14]\]

CYP2C9 is the principal enzyme involved in the metabolic clearance of the more potent S-enantiomer of warfarin and is responsible for a large inter-individual variation in dose. Studies indicate that patients with the common, functionally defective ^\*^2 (*430C* \>*T*) and ^\*^3 (*1075A* \>*C*) allelic variants of the *Cytochrome P450 enzyme 2C9* (*CYP2C9*) require significantly lower doses, take longer time to achieve stabilized dose, and are at a higher risk for serious bleeding that are patients without these variants.\[[@ref15][@ref16]\] Coumarin-based anti-coagulants act by inhibition of vitamin K epoxide reductase complex 1 (VKORC1), leading to depletion of reduced vitamin K and thereby interfering with the synthesis of vitamin K-dependent clotting factors, resulting in anti-coagulation. Studies have revealed a non-coding polymorphism in the *VKORC1* (-1639G \>A) to be associated with warfarin and acenocoumarol dose variability.\[[@ref17]--[@ref19]\]

There is a dearth of knowledge of coumarin response profile in the Asian-Indian population, as no pharmacogenetic studies have been carried out with respect to coumarin anti-coagulants in the population till date. Hence, the current preliminary study was undertaken with an aim to predict coumarin sensitivity in an Asian-Indian cohort with an inherited thrombophilia risk factor (Factor V Leiden mutation carriers). This specific cohort was chosen, as they may have a higher possibility of requiring oral anti-coagulation therapy than the general population. Based on the frequency of the *CYP2C9* ^\*^2, ^\*^3 and *VKORC1*-1639G \>A genotype combinations, the study aims to identify the proportion of those who are (i) hypersensitive to coumarin, as they may require reductions in coumarin dose and have an increased risk of bleeding and, (ii) normal sensitivity to coumarin, as they are known to require higher dose to achieve therapeutic anticoagulation.

Materials and Methods {#sec1-2}
=====================

The study was carried out at the Centre of Medical Genetics in a tertiary health care facility in India. The study protocol was approved by the Hospital\'s Research Ethics Committee and is in accordance with the ethical standards of the World Medical Association\'s Helsinki Declaration.

 {#sec2-1}

### Study population {#sec3-1}

Retrospective analysis of Factor V Leiden mutation data in the 13 years period from 1997 through 2010 was carried out. Reports of individuals referred for FVL mutation molecular genetic testing at the study Center were analyzed, and all those detected as carriers of at least one mutant allele were included in the current study. Written informed consent was obtained from all subjects prior to the test. These samples were referred for testing by physicians across the country from departments of vascular surgery, obstetrics, and medical genetics.

### Detection of factor V Leiden mutation (1691G \>A) {#sec3-2}

DNA was isolated from whole blood using standard salt-extraction method.\[[@ref20]\] Genotyping of *F5* 1691G \>A variant was done by restriction enzyme digestion of PCR-amplified DNA based on previously published protocol\[[@ref21]\] with modifications.

### Genotyping of CYP2C9 ^\*^2 (c.430C \>T; rs1799853); CYP2C9 ^\*^3 (c.1075A \>C; rs1057910); VKORC1 ^\*^2 (c.-1639G \>A; rs9923231) {#sec3-3}

The three polymorphisms were genotyped using polymerase chain reaction followed by restriction enzyme digest as described previously\[[@ref22][@ref23]\] with modifications.

### Statistical analysis {#sec3-4}

Chi-square test was applied (using SPSS statistical package version 15.0) to analyze if the genotype frequencies were in Hardy Weinberg equilibrium. A *P* value of less than 0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

In the 13 year period from 1997 through 2010, out of the 1368 individuals tested, 61 unrelated individuals (18 males; 43 females) were detected to be carriers of the FVL mutation (two homozygous and 59 heterozygous) by molecular genetic testing at the study Center. The common reasons for referral were pregnancy-associated complications, venous or arterial thrombosis, and activated protein C resistance. The age of the subjects ranged from 24 to 52 years (mean = 31 + 7.3 years), and majority (59, 96.7%) were ethno-geographically North Indians (Indo-European linguistic ethnic group). The other two belonged to West India origin.

The observed genotype and allele frequencies of *CYP2C9* (^\*^2, ^\*^3) and *VKORC1*-1639G \>A \[[Table 1](#T1){ref-type="table"}\] was in Hardy Weinberg Equilibrium. Analysis showed that 32.8% (20) were carriers of the *CYP2C9* ^\*^ 2 or ^\*^3 alleles, and 29.5% (18) were carriers of the *VKORC1*-1639A allele. The combined *CYP2C9/VKORC1* genotype profile \[[Figure 1](#F1){ref-type="fig"}\] reveals that six (9.7%) individuals had two of the three variant alleles (heterozygous or homozygous for *CYP2C9* ^\*^ 2, ^\*^3, *VKORC1*-1639G \> A). Similar fractions of study population were observed to be heterozygous for a variant allele (28, 45.9%) and homozygous for wild-type alleles for all three polymorphisms (27, 44.3%).

###### 

Genotype and allele frequencies of *CYP2C9* and *VKORC1* in factor V Leiden mutation carriers
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![*CYP2C9*/*VKORC1* genotype profile and (inset) frequency of coumarin-response genotype groups in subjects at high risk for thrombophilia (FVL carriers): Individuals with two variant *CYP2C9/VKORC1* genotypes (either compound heterozygous or homozygous) were grouped as 'hyper' sensitive (included ^\*^2 ^\*^ 3/GG; ^\*^1 ^\*^ 3/AG, ^\*^1 ^\*^ 2/AG and ^\*^1 ^\*^1/AA) and are indicated by grey bars. Those with single heterozygous polymorphism including ^\*^1 ^\*^ 1/AG; ^\*^1 ^\*^2/GG, and ^\*^1 ^\*^ 3/GG were grouped to have 'moderate' sensitivity and are indicated with dark grey bars. The wild-type *CYP2C9/VKORC1* (^\*^1 ^\*^1/GG) are indicated with black bars and comprise those with 'normal' sensitivity. The inset bar graph depicts the total frequency of the three estimated coumarin sensitivity groups](IJHG-18-326-g002){#F1}

Conclusion {#sec1-4}
==========

Previous studies have proved that despite individualization of dose to compensate for variation in patients' age, weight, diet, clinical indication, and concurrent use of other medications, the three common genetic variants (*CYP2C9* ^\*^2, ^\*^3 and *VKORC1*-1639G \>A) have a significant effect on a variety of anti-coagulation-related outcomes such as therapeutic dose requirement, time taken to achieve stable dosing, and adverse effects.\[[@ref23][@ref24]\] The *VKORC1* polymorphism -1639A accounts for 19% to 30% of variance in the dose of warfarin, while *CYP2C9* SNPs (^\*^2, ^\*^3) have a contribution of 3.2% to 12%.\[[@ref25][@ref26]\] With regard to dose variability of acenocoumarol, *CYP2C9* ^\*^ 3, *VKORC1*-1639A and age are known to explain 50% to 55% inter-individual variance.\[[@ref27][@ref28]\]

The present study analyzes the frequency of these common *CYP2C9* and *VKORC1* SNPs in a total of 122 chromosomes (*n* = 61) of individuals at high risk for hereditary thrombophilia (FVL mutation carriers). The study shows that 55.6% of the study population with one or more variant genotypes (*CYP2C9* ^\*^2, ^\*^3, *VKORC1*-1639G \>A) are likely to be sensitive to coumarin anti-coagulants and may require less than average dosages and harbor an increased risk for drug-induced adverse effects. Similarly, a smaller study in a multiethnic population\[[@ref29]\] reported that 83% of individuals at high risk of thrombophilia (FVL and prothrombin mutation carriers) were carriers of the same three polymorphisms. This magnified proportion of warfarin-sensitive group in the previous study\[[@ref29]\] may be attributed to variation in ethnic origin and/or sample size (*n* = 35 versus *n* = 61 in present study).

FVL mutation contributes to 15.8% of venous thrombosis in Asian Indians\[[@ref30]\] and 31.8% in Caucasians.\[[@ref31]--[@ref33]\] Although the thrombophilic prothrombin mutation 20210G \>A (*F2*) is common in the white and Caucasian populations, it is rare in the Asian Indian general population.\[[@ref30][@ref34][@ref35]\] This was confirmed by the findings at the Center of Medical Genetics, Sir Ganga Ram Hospital, India. In the 13-year period (1997 through 2010), none of the cases referred for prothrombin mutation analysis 20210G \>A were positive for the mutation. Considering the low frequency of the mutation in the Asian Indians, the present study did not include any patients with the prothrombin mutation.

The current pilot study was carried out in a cohort of FVL mutation carriers who were not on prophylactic or therapeutic oral anti-coagulant therapy, hence accurate maintenance dose estimation and prevalence of bleeding events was not viable in the present cohort. Additionally, lack of data on non-genetic determinants of coumarin response (co-morbidities, concomitant interacting medications, weight, height, smoking status, and vitamin K intake) may reduce the efficacy of predicted coumarin sensitivity profiles in the current study. However, the study does take into account the three most important genetic markers for coumarin sensitivity, which have also been approved for estimating dose by the U.S.A. Food and Drug Administration.

In clinical practice, most patients on anti-coagulation therapy are known to stabilize on intermediate dosages and hence, the patient populations that are known to benefit most from pre-prescription genetic testing are those at the ends of the coumarin sensitivity spectrum i.e., the hyper-and normal sensitivity groups (54%) in whom the optimum anti-coagulation may be achieved with minimal dosages or higher than average dosages, respectively. Additionally, testing will also identify the 55.6% subjects (hyper-and moderately sensitive groups) who are at an elevated risk of drug-induced adverse effects. For future research, a more systematic, comparative study with larger cohort of individuals with and without inherited thrombophilia, prospectively treated with oral anti-coagulants, is required to explore drug response with actual maintenance dose and prevalence of adverse drug reactions in the two groups. The current study provides preliminary evidence for the need of pre-prescription genotyping in patients in whom oral anti-coagulant therapy may be necessary either due to the inherited predisposition to thrombophilia or due to other thrombophilic risk factors.
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